US Court Paves the Way for Sun Pharma to Release Autoimmune Drug
Click to start listening
Synopsis
Sun Pharmaceutical Industries has gained crucial approval from a US court, allowing the launch of its autoimmune disorder treatment, Leqselvi (Deuruxolitinib), in the US market. This decision clears previous patent-related restrictions and enables the company to move forward with its launch plans.
Key Takeaways
- Sun Pharma received a favorable ruling from a US court.
- The drug Leqselvi treats autoimmune disorders causing hair loss.
- The US Court of Appeals lifted previous restrictions on the drug's launch.
- The case involved a patent dispute with Incyte Corporation.
- Sun Pharma plans to announce launch details soon.
Mumbai, April 10 (NationPress) Sun Pharmaceutical Industries announced on Thursday that it has received significant relief from a US court, allowing the company to introduce its new medication Leqselvi (Deuruxolitinib) in the American market.
This medication is aimed at treating an autoimmune disorder characterized by patchy hair loss. The US Court of Appeals for the Federal Circuit ruled in favor of Sun Pharma by lifting the previous restrictions that prevented the launch of Leqselvi.
The court's decision to vacate the preliminary injunction is effective immediately, enabling Sun Pharma to proceed with the drug's launch in the US.
This case centers around a patent dispute involving Sun Pharma and Incyte Corporation. A lower court in New Jersey had previously issued an order that postponed the launch of Leqselvi, which includes the compound deuruxolitinib.
Sun Pharma contested this ruling in the US Court of Appeals.
On April 9, 2025, the court conducted oral arguments concerning the case. Shortly after the hearing concluded, the court delivered its decision favoring Sun Pharma, thus lifting the earlier restrictions.
“Sun Pharma had been embroiled in a patent infringement litigation with Incyte Corporation regarding LEQSELVI (deuruxolitinib). On April 9, the US Court of Appeals for the Federal Circuit held oral arguments on the company's appeal against the US District Court for the District of New Jersey decision that had previously granted a preliminary injunction delaying the launch of Leqselvi in the US,” the company stated in a regulatory filing.
Despite the ongoing legal battle between the two firms, the recent court ruling has cleared the way for Sun Pharma to launch Leqselvi in the US without any current legal limitations.
In their regulatory filing, Sun Pharma confirmed that there are no longer any court orders obstructing the launch of Leqselvi. The company also indicated that it would announce its plans for the drug's launch shortly.
